Alliance Pharma logo

APH - Alliance Pharma Share Price

86.33p 0.0  0.0%

Last Trade - 3:16pm

Sector
Healthcare
Size
Mid Cap
Market Cap £459.9m
Enterprise Value £514.9m
Revenue £131.3m
Position in Universe 597th / 1800
Bullish
Bearish
Unlock APH Revenue
Momentum
Relative Strength (%)
1m +9.40%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.16%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
43.5 48.3 97.5 101.6 118.2 135.6 135.9 147.3 +25.5%
-8.9 -16.1 +35.9 +28.9 -2.0 +7.3 -13.4 +10.6
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, AlliancePharma plc revenues decreased 7% to £61.7M. Net losstotaled £1.8M vs. income of £12.1M. Revenues reflect Europe& Middle East & Africa (EMEA) (Region) segment decrease of6% to £44.8M, Asia Pacific and china segment decrease of 9%to £13.3M. Net loss reflects Amortised Finance Issue Costsincrease of 15% to £267K (expense), Interest incomedecrease of 23% to £10K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for APH
Graphical History

Revenue

APH Revenue Unlock APH Revenue

Net Income

APH Net Income Unlock APH Revenue

Normalised EPS

APH Normalised EPS Unlock APH Revenue

PE Ratio Range

APH PE Ratio Range Unlock APH Revenue

Dividend Yield Range

APH Dividend Yield Range Unlock APH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APH EPS Forecasts Unlock APH Revenue
Profile Summary

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international. The Company's therapeutic areas of focus include cardiovascular, central nervous system, child health, consumer health, dermatology, endocrinology, gastroenterology, obstetrics and gynecology, oral health, oncology, stoma care, toxicology and travel health. The Company's product categories include prescription only medicines, over the counter medications, medical devices, cosmetics and nutritional supplements. The Company's products include SkinSafe, Lift Plus, AbsorbaGel, DeoGel, LaVera, ClearWay, Gelclair, ImmuCyst 81mg, Hydromol, MacuShield, Lypsyl, Anbesol Adult Strength Gel, MolluDab and Ashton & Parsons Infants' Powders.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated June 26, 2001
Public Since November 22, 2001
No. of Shareholders: n/a
No. of Employees: 200
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 532,919,111
Free Float (0.0%)
Eligible for
ISAs
SIPPs
APH Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for APH
Upcoming Events for APH
Frequently Asked Questions for Alliance Pharma
What is the Alliance Pharma share price?

As of 3:16pm, shares in Alliance Pharma are trading at 86.33p, giving the company a market capitalisation of £459.9m. This share price information is delayed by 15 minutes.

How has the Alliance Pharma share price performed this year?

Shares in Alliance Pharma are currently trading at 86.33p and the price has moved by 4.86% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Alliance Pharma price has moved by 16.27% over the past year.

What are the analyst and broker recommendations for Alliance Pharma?

Of the analysts with advisory recommendations for Alliance Pharma, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Alliance Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Alliance Pharma next release its financial results?

Alliance Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Alliance Pharma dividend yield?

The Alliance Pharma dividend yield is 0.62% based on the trailing twelve month period.

Does Alliance Pharma pay a dividend?

Last year, Alliance Pharma paid a total dividend of 0.01, and it currently has a trailing dividend yield of 0.62%. Looking ahead, Alliance Pharma has not announced an ex-dividend date yet.

When does Alliance Pharma next pay dividends?

Alliance Pharma has yet to annouce their ex-dividend date. The historic dividend yield on Alliance Pharma shares is currently 0.62%.

How do I buy Alliance Pharma shares?

To buy shares in Alliance Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Alliance Pharma?

Shares in Alliance Pharma are currently trading at 86.33p, giving the company a market capitalisation of £459.9m.

Where are Alliance Pharma shares listed? Where are Alliance Pharma shares listed?

Here are the trading details for Alliance Pharma:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: APH
What kind of share is Alliance Pharma?

Based on an overall assessment of its quality, value and momentum, Alliance Pharma is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Alliance Pharma share price forecast 2021?

Shares in Alliance Pharma are currently priced at 86.33p. At that level they are trading at 7.38% discount to the analyst consensus target price of 93.21.

Analysts covering Alliance Pharma currently have a consensus Earnings Per Share (EPS) forecast of 0.04487 for the next financial year.

How can I tell whether the Alliance Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alliance Pharma. Over the past six months, the relative strength of its shares against the market has been 3.88%. At the current price of 86.33p, shares in Alliance Pharma are trading at 15.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Alliance Pharma PE Ratio?

The Alliance Pharma PE ratio based on its reported earnings over the past 12 months is 17.51. The shares are currently trading at 86.33p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Alliance Pharma?

Alliance Pharma's management team is headed by:

Peter Butterfield - CEO
David Cook - NEC
Janice Timberlake - CHO
Dan Thomas - OTH
Stephen Kidner - COO
Nigel Clifford - NID
Andrew Franklin - CFO
Jo Couilliard - NID
Richard Jones - NID
Alex Duggan - OTH
Chris Chrysanthou - SEC
Who are the major shareholders of Alliance Pharma?

Here are the top five shareholders of Alliance Pharma based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 9.09% (48.4m shares)
Slater Investments Ltd. Investment Advisor/Hedge Fund
Percentage owned: 7.78% (41.4m shares)
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund
Percentage owned: 5.98% (31.9m shares)
Slater Growth Fund Mutual Fund
Percentage owned: 5.81% (30.9m shares)
Dawson (John Andrew) Individual Investor
Percentage owned: 5.62% (30.0m shares)
Similar to APH
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.